PRECISE begins enrollment, looks to improve CT intervention
A DCRI team has begun enrollment for a clinical trial investigating the optimal evaluation strategies for people with symptoms of coronary artery disease. PRECISE, or Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization, will enroll 2,100 patients across 100 sites in the U.S, Canada, and Europe. The trial is led by the DCRI’s Pamela Douglas, MD.
The DCRI welcomes new faculty member
Jessilyn Dunn, PhD, is a faculty member in Duke’s Departments of Biomedical Engineering; Biostatistics and Bioinformatics.
The past, present, and future of IPF research at the DCRI
Little is known about the cause of idiopathic pulmonary fibrosis (IPF), a devastating disease that is characterized by progressive scarring of the lung tissue that affects a person’s ability to bre
TRANSFORM-HF team pioneers new type of clinical trial
Heart failure patients have a tendency to accumulate excess fluid in the body, which can lead to debilitating symptoms such as shortness of breath and swelling. Loop diuretic medication, aims to prevent accumulation of this fluid and is the cornerstone treatment for heart failure signs and symptoms. With more than six million Americans affected by heart failure, and about one million hospitalized every year, a new DCRI study called TRANSFORM-HF will directly compare two well-known diuretics – furosemide and torsemide – to determine which is the most effective.
The DCRI’s Sheng Luo on the benefit of biostatistics
DCRI biostatisticians play a key role in many of the organization’s projects.
DCRI-led think tank addresses opportunities and challenges of digital technology in health care
The DCRI brought together national leaders to address the promise and challenges facing digital health technologies in the transformation of health care.
DCRI, University of Oxford to collaborate on chronic kidney disease study
EMPA-KIDNEY will study the effects of empagliflozin in CKD patients with and without diabetes.
Heart patients help doctors determine best aspirin dose
The ADAPTABLE study, coordinated by the DCRI, will enroll as many as 15,000 cardiac patients to determine the optimal aspirin dose.
DCRI to coordinate national study of childhood health
The DCRI will serve as the coordinating center for ECHO, which will examine how environmental factors affect childhood health.
Boehringer Ingelheim and DCRI expand collaboration to create largest patient registry for IPF
Boehringer Ingelheim Pharmaceuticals, Inc. and the DCRI announced today the expansion of the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.